Harmony Biosciences Holdings, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jeffrey Dayno
- Full Time Employees
- 293
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 630 West Germantown Pike Plymouth Meeting PA United States of America 19462
- IPO Date
- Aug 19, 2020
- CIK
- 0001802665
- Website
- harmonybiosciences.com
- Similar Companies
- Business
- Harmony Biosciences Holdings, Inc. develops and commercializes therapies for rare neurological disorders, primarily focusing on innovative treatments to address unmet medical needs. Its core product portfolio centers on WAKIX (pitolisant), the first and only FDA-approved oral medication for excessive daytime sleepiness in adult patients with narcolepsy. The company also develops pipeline candidates such as EPX-100 (clemizole hydrochloride) for Dravet syndrome, EPX-200 (lorcaserin) targeting other rare neurological conditions, and CBS-104, a regenerative cellular therapy for refractory epilepsy. Harmony Biosciences markets these products primarily in the United States and pursues expansion through clinical development in other rare disease indications. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, the company strategically expanded by acquiring Epygenix Therapeutics in 2024, gaining late-stage epilepsy assets and enhancing its CNS rare disease pipeline. Recently, it announced positive results from a pivotal bioequivalence study for pitolisant’s gastro-resistant formulation, setting the stage for a New Drug Application submission in early 2026, and is advancing phase 3 clinical trials for EPX-100 in Dravet syndrome with topline data expected in 2026. Additionally, Harmony entered into a strategic financing agreement with Blackstone in 2024, securing up to $330 million to support its growth initiatives. The company actively presents clinical data at major scientific forums and continues developing multiple CNS programs targeting rare neurological disorders across the U.S. and beyond.
Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026
HRMY Posts Preliminary Q2 Revenues, Announces CFO Transition
Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition
Wall Street Analysts See a 27.35% Upside in Harmony Biosciences (HRMY): Can the Stock Really Move This High?
HRMY vs. AMGN: Which Stock Is the Better Value Option?
5 Low Price-to-Book Value Stocks to Buy in July for Solid Returns
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?
Best Value Stocks to Buy for July 14th
Is HRMY Stock Worth Buying With Neutral Signals and Cheap Valuation?
Harmony Biosciences Stock Outlook as Wakix Growth Meets Pipeline
HRMY Growth Trends Beyond Wakix Could Shape Its Next Growth Phase
Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting
Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting
Harmony Biosciences Holdings, Inc. (HRMY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Harmony Biosciences to Participate in Upcoming Investor Conferences
Harmony Biosciences to Participate in Upcoming Investor Conferences
Harmony Biosciences Holdings, Inc. (HRMY) Q1 2026 Earnings Call Transcript
Harmony Biosciences Holdings, Inc. (HRMY) Q1 Earnings and Revenues Miss Estimates
Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities
Looking for a Growth Stock? 3 Reasons Why Harmony Biosciences (HRMY) is a Solid Choice